So it begins…dubbed the ‘Miracle Cure’ for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK.
Just 2 days before Christmas, the French billion euro Biotech, Cellectis, submitted a clinical trial application to the Medicines & Healthcare products Regulatory Agency (MHRA). Specifically, the request was to approve initiation of the First-in-Human clinical investigation for UCART19 in leukemia.
The candidate in question, UCART19, is a universal CAR-T therapy which has a particular T-cell receptor engineered to target Acute Lymphoblastic leukemia (ALL) and Chronic Lymphocytic leukemia (CLL). You can read more about CAR-T therapy for cancers in our December review..
We also recently met André Choulika, CEO of Cellectis for an interview on the progress of this ‘Miracle cure’ for Leukemia (so labelled by the press). However, on UCART19 he was keen to refute the hype surrounding the latest application in the UK, which saved a baby girl with terminal ALL a couple of months back:
It will bring something really great to Haematology field,